Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants

International Journal of Cancer

Volumn 111, Issue 1, 2004, Pages 86-95

  Chang, Sun Young ^a,b   Lee, Kyung Chul ^a   Ko, Sung Youl ^a   Ko, Hyun Jeong ^a   Kang, Chang Yuil ^a,b  

^a Seoul National University   (South Korea)

^b PanGenomics Inc   (South Korea)

Author keywords

Adjuvant; Cytokine; DNA vaccine; Eta 1; Flt3L; GM CSF; Her 2 neu; IL 12; IL 15; IL 18; IL 23

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLT3 LIGAND; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 23; MEMBRANE PROTEIN; TUMOR ANTIGEN; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENETIC CODE; HEMATOPOIESIS; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE NEU; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; VACCINATION;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA; COLONIC NEOPLASMS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; PLASMIDS; RECEPTOR, ERBB-2; VACCINES, DNA;

EID: 3042817388     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20232     Document Type: Article

References (58)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-36.
2. Gullick WJ, Love SB, Wright C, Bames DM, Gusterson B, Harris AL, Altman DG. C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-8.
3. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
4. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999; 26:89-95.
5. Pupa SM, Invernizzi AM, Forti S, Di Carlo E, Musiani P, Nanni P, Lollini PL, Meazza R, Ferrini S, Menard S. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther 2001;8:75-9.
6. Lu Y, Wei YQ, Tian L, Zhao X, Yang L, Hu B, Kan B, Wen YJ, Liu F, Deng HX, Li J, Mao YQ, et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 2003;170:3162-70.
7. Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000;60:3569-76.
8. Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
9. Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, Heilbrun L, Jones RF. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999;81:748-54.
10. Piechocki MP, Pilon SA, Wei WZ. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 2001;167:3367-74.
11. Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, Spadaro M, Colombo MP, Amici A, Lollini PL, Musiani P, Forni G. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003;111: 1161-70.
12. Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 1998;58:1965-71.
13. Lee JY, Kim DH, Chung Y, Shin SU, Kang CY. Comparison of the antitumor efficacies of Her-2/neu DNA vaccines inducing contrasting IgG immunity but comparable CTL activity in mice. Vaccine 2003; 21:521-31.
14. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
15. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-48.
16. Bueler H, Mulligan RC. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol Med 1996;2:545-55.
17. Kim JJ, Simbiri KA, Sin JI, Dang K, Oh J, Dentchev T, Lee D, Nottingham LK, Chalian AA, McCallus D, Ciccarelli R, Agadjanyan MG, et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res 1999;19:77-84.
18. Geissler M, Gesien A, Wands JR. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids. J Immunol 1997;159:5107-13.
19. Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997; 158:4591-601.
20. Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishioka K, Fukushima J, Miyazaki J, Wahren B, Okuda K. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997;159:3638-47.
21. Herrera AM, Rodriguez EG, Hernandez T, Sandez B, Duarte CA. A family of compact plasmid vectors for DNA immunization in humans. Biochem Biophys Res Commun 2000;279:548-51.
22. Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci 1999;49: 179-88.
23. Lee Y, Park EJ, Yu SS, Kim DK, Kim S. Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: implication for gene therapy of ischemic diseases. Biochem Biophys Res Commun 2000;272:230-5.
24. Baek KM, Ko SY, Lee M, Lee JS, Kim JO, Ko HJ, Lee JW, Lee SH, Cho SN, Kang CY. Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65. Vaccine 2003;21:3684-9.
25. Lee JW, Kim K, Jung SH, Lee KJ, Choi EC, Sung YC, Kang CY. Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies. J Virol 1999;73:11-8.
26. Kim KM, Shin EY, Moon JH, Heo TH, Lee JY, Chung Y, Lee YJ, Cho HM, Shin SU, Kang CY. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen. Int J Cancer 2002;102:428-34.
27. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Kanematsu T, Shiku H. Peptides derived from a wild-type murine proto-oncogne c-erbB-2/Her2/neu can induce CTL and tumor suppression in syngenic hosts. J Immunol 1997;159:1336-43.
28. Mwangi W, Brown WC, Lewin HA, Howard CJ, Hope JC, Baszler TV, Caplazi P, Abbott J, Palmer GH. DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colony-stimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses induced by DNA vaccination of outbred animals. J Immunol 2002;169:3837-46.
29. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, Davies ME, Shiver JW, et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 2002;168:562-8.
30. Lee SW, Cho JH, Sung YC. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 1998;72:8430-6.
31. Schuler T, Blankenstein T. CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol 2003;170:4427-31.
32. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine 2001; 19:2647-56.
33. Sun X, Hodge LM, Jones HP, Tabor L, Simecka JW. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine 2002;20:1466-74.
34. Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S, Okuda K, Miyagi Y, Aoki I, Nishioka K, Klinman D, Okuda K. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000;164:3102-11.
35. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000;18:927-74.
36. Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar S, Hoffman SL, Weiss WR. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 2000;165:3772-81.
37. Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J, Caron D, Lebsack ME, MacKenna H. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000;96:878-84.
38. Steptoe RJ, Li W, Fu F, O'Connell PJ, Thomson AW. Trafficking of APC from liver allografts of Flt3L-treated donors: augmentation of potent allostimulatory cells in recipient lymphoid tissue is associated with a switch from tolerance to rejection. Transpl Immunol 1999;7:51-7.
39. Li W, Lu L, Wang Z, Wang L, Fung JJ, Thomson AW, Qian S. Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors. Transplantation 2001;8:1423-32.
40. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 1997;3:625-31.
41. Miller G, Pillarisetty VG, Shah AB, Lahrs S, DeMatteo RP. Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties. J Immunol 2003;170:3554-64.
42. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G. Granulocyte-colony stimulating factor gene suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173:889-97.
43. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001;97:339-45.
44. Stockmeyer B, Valerius T, Repp R, Heijnen IA, Buhring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JG. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 1997;57:696-701.
45. Houghton AN, Lloyd KO. Stuck in the MUC on the long and winding road. Nat Med 1998;4:270-1.
46. Boon T, Cerottini JC, Van den Eynde B, Van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
47. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997;3:342-9.
48. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. Hanson HL. Eradication of established tumors by CD8 + T cell adoptive immunotherapy. Immunity 2000;13:265-76.
49. Ward PL, Koeppen HK, Hurteau T, Rowley DA, Schreiber H. MHC Class I and unique antigen expression by tumors that escaped from CD8 + T cell dependent surveillance. Cancer Res 1990;50:3851-8.
50. Greenberg PD, Cheever MA, Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1 + 2- lymphocytes. J Exp Med 1981;154:952-63.
51. Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musiani P, Modesti A, Cavallo F, Di Pierro F, Novelli F, Forni G. An efficient Th-2-type memory follows CD8+ lymphocyte driven and eosinophil mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994;153:5659-73.
52. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
53. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999;17:19-49.
54. Yang J, Zhu H, Murphy TL, Ouyang W, Murphy KM. IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. Nat Immunol 2001;2:157-64.
55. Belladonna ML, Renauld JC, Bianchi R, Vacca C, Fallarino F, Orabona C, Fioretti MC, Grohmann U, Puccetti P. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol 2002;168:5448-54.
56. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-4.
57. Nakamura K, Okamura H, Nagata K, Komatsu T, Tamura T. Purification of a factor which provides a costimulatory signal for gamma interferon production. Infect Immun 1993;61:64-70.
58. Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003;9:33-9.